From: Immunotherapy for Merkel cell carcinoma: a turning point in patient care
Drug name
Drug class
N
Number of prior systemic therapies
ORR (%)
Reference
Avelumab
Anti-PD-L1
88
1–4
33
[40]
29
0
65
[53]
Nivolumab
Anti-PD-1
15
73*
[44]
10
1–2
50*
Pembrolizumab
26
56
[35]